Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers

[1]  Jennifer A. Smith,et al.  Population Pharmacokinetics of Motexafin Gadolinium in Adults With Brain Metastases or Glioblastoma Multiforme , 2005, Journal of clinical pharmacology.

[2]  L. Gordon,et al.  Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. , 2005, Blood.

[3]  M. Egorin,et al.  A phase 1 trial of motexafin gadolinium and docetaxel for advanced solid tumors. , 2004, Journal of Clinical Oncology.

[4]  B. Erickson,et al.  Phase II Study of External Irradiation and Weekly Paclitaxel for Nonmetastatic, Unresectable Pancreatic Cancer: RTOG-98-12 , 2004, American journal of clinical oncology.

[5]  Daniel Normolle,et al.  Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  W. Curran,et al.  Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  W. Curran,et al.  Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Strawderman,et al.  Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Sessler,et al.  Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. , 2001, International journal of radiation oncology, biology, physics.

[10]  Daniel Quirk,et al.  Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial. , 2001, International journal of radiation oncology, biology, physics.

[11]  Douglas B. Evans,et al.  Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? , 2001, International journal of radiation oncology, biology, physics.

[12]  R Timmerman,et al.  Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Sessler,et al.  Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. , 2000, Biochemical pharmacology.

[14]  M. Egorin,et al.  Sensitive high-performance liquid chromatographic assay for motexafin gadolinium and motexafin lutetium in human plasma. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[15]  J A Koutcher,et al.  In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. , 1999, International journal of radiation oncology, biology, physics.

[16]  D I Rosenthal,et al.  A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  B. Erickson,et al.  Review article: Biliary tree malignancies , 1998 .

[18]  H. Bjarnason,et al.  Biliary tree malignancies: The University of Minnesota experience , 1997, Journal of surgical oncology.

[19]  J. Sessler,et al.  Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Barkin,et al.  Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‐fluorouracil), and high dose radiation + 5‐fluorouracil. The gastrointestinal tumor study group , 1981, Cancer.

[21]  H. Akaike.  A Bayesian extension of the minimum AIC procedure of autoregressive model fitting , 1979 .

[22]  A Schumitzky,et al.  A program package for simulation and parameter estimation in pharmacokinetic systems. , 1979, Computer programs in biomedicine.

[23]  W. Curran,et al.  Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. Erickson,et al.  Biliary tree malignancies. , 1998, Journal of Surgical Oncology.

[25]  Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. , 1988, Journal of the National Cancer Institute.

[26]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.